

Basal Cell Carcinoma Therapeutic Pipeline Market Review, H2 2016

Basal Cell Carcinoma Treatment Pipeline Review H2 2016

PUNE, INDIA, October 14, 2016

/EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for [Basal Cell Carcinoma](#) (Basal Cell Epithelioma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and

development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and features dormant and discontinued projects.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/477388-basal-cell-carcinoma-basal-cell-epithelioma-pipeline-review-h1-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Basal Cell Carcinoma (Basal Cell Epithelioma)
- The report reviews pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental



WISE GUY
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

activities

- The report reviews key players involved Basal Cell Carcinoma (Basal Cell Epithelioma) therapeutics and enlists all their major and minor projects
- The report assesses Basal Cell Carcinoma (Basal Cell Epithelioma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Buy 1-User PDF @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=477388

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Basal Cell Carcinoma (Basal Cell Epithelioma) Overview 8

Therapeutics Development 9

Pipeline Products for Basal Cell Carcinoma (Basal Cell Epithelioma) - Overview 9

Pipeline Products for Basal Cell Carcinoma (Basal Cell Epithelioma) - Comparative Analysis 10

Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics under Development by Companies 11

Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics under Investigation by Universities/Institutes 13

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Basal Cell Carcinoma (Basal Cell Epithelioma) - Products under Development by Companies 17

Basal Cell Carcinoma (Basal Cell Epithelioma) - Products under Investigation by Universities/Institutes 18

Basal Cell Carcinoma (Basal Cell Epithelioma) - Companies Involved in Therapeutics Development

19

Biofrontera AG 19
Biosceptre (Aust) Pty Ltd 20
Genextra S.p.a. 21
Ignyta, Inc. 22
Laboratories Ojer Pharma S.L. 23
MediGene AG 24
Merck & Co., Inc. 25
Novartis AG 26
Provectus Biopharmaceuticals, Inc. 27
Redx Pharma Plc 28
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 29
Transgene SA 30
Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Combination Products 32
Assessment by Target 33

Access Report @ <https://www.wiseguyreports.com/reports/477388-basal-cell-carcinoma-basal-cell-epithelioma-pipeline-review-h1-2016>

Follow Us:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.